A5104909703- Gastric Cancer Management and Outcomes
- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- Ovarian cancer diagnosis and treatment
- Global Cancer Incidence and Screening
- Economic and Financial Impacts of Cancer
- Drug-Induced Hepatotoxicity and Protection
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Biomedical Research and Pathophysiology
- Poisoning and overdose treatments
- Advances in Oncology and Radiotherapy
- Endometrial and Cervical Cancer Treatments
- Genetic factors in colorectal cancer
Peking Union Medical College Hospital
2024
Academy of Medical Sciences
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
First Affiliated Hospital of Xinjiang Medical University
2024
Xinjiang Medical University
2024
Sichuan Mianyang 404 Hospital
2022
Epithelial ovarian cancer (EOC) is a lethal form of gynecological malignancy. Some EOC patients experience relapse after standard primary debulking surgery (PDS) and adjuvant chemotherapy (ACT). Identifying molecular residual disease (MRD) by circulating tumor DNA (ctDNA) detection can timely signal the potential for relapse. However, research on usage ctDNA MRD in limited. Fifty-one who received PDS ACT were included. Targeted sequencing based panel 1021 cancer-related genes, along with...
Abstract We explored the potential value of alcohol dehydrogenase (ADH) inhibitor isovaleramide (ISO) in treatment acute ethylene glycol (EG) poisoning‐induced kidney injury. Sprague–Dawley rats were divided into control, EG, EG + ISO (10 mg/kg) and (20 groups. It is found that intervention significantly reduced ADH activity liver tissue by using visible spectrophotometry, inhibited vivo metabolism gas chromatography, lowered levels toxic metabolites glycolic acid oxalic high‐performance...
Background: Treatment strategies for refractory recurrent or metastatic cervical cancer (R/M CC) are scarce. The synergistic antitumor effects of toripalimab plus standard therapy as first-line treatment have been demonstrated in various cancers. Therefore, we evaluated the efficacy and safety bevacizumab platinum-based chemotherapy R/M CC irrespective programmed cell death ligand 1 (PD-L1) status.Methods: Patients were administered (240 mg) + (7·5 mg/kg) combined with once every three weeks...